Literature DB >> 25479804

Performance of self-collected cervical samples in screening for future precancer using human papillomavirus DNA testing.

Carolina Porras1, Allan Hildesheim2, Paula González2, Mark Schiffman2, Ana Cecilia Rodríguez2, Sholom Wacholder2, Silvia Jiménez2, Wim Quint2, Diego Guillen2, Aimée R Kreimer2, Rolando Herrero2.   

Abstract

BACKGROUND: Self-collected human papillomavirus (HPV) testing could reduce barriers to cervical cancer screening, with performance comparable to clinician-collected specimens. The ability of self-collected specimens to cross-sectionally and prospectively detect precursor lesions was investigated in an HPV vaccine randomized trial in Costa Rica.
METHODS: In the trial, 7466 women age 18 to 25 years received an HPV16/18 or control vaccine and were followed at least annually for four years. In this secondary analysis, we included all women who provided a self-collected cervicovaginal specimen six months after enrollment (5109 women = full analytical cohort). A subset (615 women = restricted cohort) also had clinician-collected specimens at the six-month postenrollment visit. High-grade squamous intraepithelial lesion or repeat low-grade squamous intraepithelial lesion prompted colposcopic referral throughout the study. HPV testing was performed with SPF10PCR/DEIA/LiPA25. Cross-sectional and prospective sensitivity, specificity, and predictive values were estimated.
RESULTS: In the full cohort, one-time HPV testing on self-collected samples detected prevalent CIN2+ with a sensitivity of 88.7% (95% confidence interval [CI] =77.0% to 95.7%) and a specificity of 68.9% (95% CI = 67.6% to 70.1%). For predicting incident CIN2+ in the subsequent four years, sensitivity was 73.9% (95% CI = 65.8% to 81.0%) and specificity 69.4% (95% CI = 68.1% to 70.7%). In the restricted cohort, for incident CIN2+, self-collected HPV was much more sensitive than cytology (80.0% vs 10.0%); relative sensitivity was 0.1 (95% CI = 0.03% to 0.5%). Furthermore, three times more women with normal baseline cytology developed incident CIN2+ than those with negative self-collected HPV. Self-collected and clinician-collected HPV testing had comparable performance. Agreement between self- and clinician-collected samples was 89.7% (kappa = 0.78, McNemar χ2 = 0.62) for carcinogenic HPV types.
CONCLUSIONS: Self-collected specimens can be used for HPV-based screening, providing sensitivity and specificity comparable with clinician-collected specimens and detecting disease earlier than cytology.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25479804      PMCID: PMC4271079          DOI: 10.1093/jnci/dju400

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  37 in total

Review 1.  Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review.

Authors:  K Nanda; D C McCrory; E R Myers; L A Bastian; V Hasselblad; J D Hickey; D B Matchar
Journal:  Ann Intern Med       Date:  2000-05-16       Impact factor: 25.391

2.  What is the concordance between the medical record and patient self-report as data sources for ambulatory care?

Authors:  Diana M Tisnado; John L Adams; Honghu Liu; Cheryl L Damberg; Wen-Pin Chen; Fang Ashlee Hu; David M Carlisle; Carol M Mangione; Katherine L Kahn
Journal:  Med Care       Date:  2006-02       Impact factor: 2.983

3.  The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period.

Authors:  Susanne Kjaer; Estrid Høgdall; Kirsten Frederiksen; Christian Munk; Adriaan van den Brule; Edith Svare; Chris Meijer; Attilla Lorincz; Thomas Iftner
Journal:  Cancer Res       Date:  2006-10-23       Impact factor: 12.701

4.  Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction.

Authors:  P E Gravitt; J V Lacey; L A Brinton; W A Barnes; J R Kornegay; M D Greenberg; S M Greene; O C Hadjimichael; L McGowan; R Mortel; P E Schwartz; R Zaino; A Hildesheim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-02       Impact factor: 4.254

5.  Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR.

Authors:  Leen-Jan van Doorn; Anco Molijn; Bernhard Kleter; Wim Quint; Brigitte Colau
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

Review 6.  Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis.

Authors:  Patrick Petignat; Daniel L Faltin; Ilan Bruchim; Martin R Tramèr; Eduardo L Franco; François Coutlée
Journal:  Gynecol Oncol       Date:  2007-02-28       Impact factor: 5.482

Review 7.  Human papillomavirus and cervical cancer.

Authors:  Mark Schiffman; Philip E Castle; Jose Jeronimo; Ana C Rodriguez; Sholom Wacholder
Journal:  Lancet       Date:  2007-09-08       Impact factor: 79.321

8.  Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.

Authors:  N W J Bulkmans; J Berkhof; L Rozendaal; F J van Kemenade; A J P Boeke; S Bulk; F J Voorhorst; R H M Verheijen; K van Groningen; M E Boon; W Ruitinga; M van Ballegooijen; P J F Snijders; C J L M Meijer
Journal:  Lancet       Date:  2007-10-04       Impact factor: 79.321

9.  Human papillomavirus and Papanicolaou tests to screen for cervical cancer.

Authors:  Pontus Naucler; Walter Ryd; Sven Törnberg; Anders Strand; Göran Wadell; Kristina Elfgren; Thomas Rådberg; Björn Strander; Bo Johansson; Ola Forslund; Bengt-Göran Hansson; Eva Rylander; Joakim Dillner
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

10.  Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

Authors:  Marie-Hélène Mayrand; Eliane Duarte-Franco; Isabel Rodrigues; Stephen D Walter; James Hanley; Alex Ferenczy; Sam Ratnam; François Coutlée; Eduardo L Franco
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

View more
  10 in total

1.  Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage.

Authors:  Kanan T Desai; Kayode O Ajenifuja; Adekunbiola Banjo; Clement A Adepiti; Akiva Novetsky; Cathy Sebag; Mark H Einstein; Temitope Oyinloye; Tamara R Litwin; Matt Horning; Fatai Olatunde Olanrewaju; Mufutau Muphy Oripelaye; Esther Afolabi; Oluwole O Odujoko; Philip E Castle; Sameer Antani; Ben Wilson; Liming Hu; Courosh Mehanian; Maria Demarco; Julia C Gage; Zhiyun Xue; Leonard R Long; Li Cheung; Didem Egemen; Nicolas Wentzensen; Mark Schiffman
Journal:  Infect Agent Cancer       Date:  2020-10-14       Impact factor: 2.965

2.  Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men: National Health and Nutrition Examination Survey (NHANES) 2013-2014.

Authors:  Jasmine J Han; Thomas H Beltran; John W Song; John Klaric; Y Sammy Choi
Journal:  JAMA Oncol       Date:  2017-06-01       Impact factor: 31.777

3.  Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.

Authors:  Carolina Porras; Sabrina H Tsang; Rolando Herrero; Diego Guillén; Teresa M Darragh; Mark H Stoler; Allan Hildesheim; Sarah Wagner; Joseph Boland; Douglas R Lowy; John T Schiller; Mark Schiffman; John Schussler; Mitchell H Gail; Wim Quint; Rebeca Ocampo; Jorge Morales; Ana C Rodríguez; Shangying Hu; Joshua N Sampson; Aimée R Kreimer
Journal:  Lancet Oncol       Date:  2020-12       Impact factor: 41.316

Review 4.  Self-Sampling for Human Papillomavirus Testing: Increased Cervical Cancer Screening Participation and Incorporation in International Screening Programs.

Authors:  Sarah Gupta; Christina Palmer; Elisabeth M Bik; Juan P Cardenas; Harold Nuñez; Laurens Kraal; Sara W Bird; Jennie Bowers; Alison Smith; Nathaniel A Walton; Audrey D Goddard; Daniel E Almonacid; Susan Zneimer; Jessica Richman; Zachary S Apte
Journal:  Front Public Health       Date:  2018-04-09

5.  Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.

Authors:  Marc Arbyn; Sara B Smith; Sarah Temin; Farhana Sultana; Philip Castle
Journal:  BMJ       Date:  2018-12-05

Review 6.  Clinical significance of human papillomavirus genotyping.

Authors:  Youn Jin Choi; Jong Sup Park
Journal:  J Gynecol Oncol       Date:  2016-03       Impact factor: 4.401

7.  An Evaluation of the Cobas4800 HPV Test on Cervico-Vaginal Specimens in Liquid versus Solid Transport Media.

Authors:  Hongxue Luo; Hui Du; Kathryn Maurer; Jerome L Belinson; Guixiang Wang; Zhihong Liu; Lijie Zhang; Yanqiu Zhou; Chun Wang; Jinlong Tang; Xinfeng Qu; Ruifang Wu
Journal:  PLoS One       Date:  2016-02-01       Impact factor: 3.240

8.  Prevalence of human papillomavirus infection and genotyping for population-based cervical screening in developed regions in China.

Authors:  Yanru Zhang; Yueyun Wang; Li Liu; Chun Guo; Zhihua Liu; Shaofa Nie
Journal:  Oncotarget       Date:  2016-09-20

9.  CyclinA1 Promoter Methylation in Self-Sampling Test.

Authors:  Shina Oranratanaphan; Malika Kengsakul; Surang Triratanachat; Nakarin Kitkumthorn; Apiwat Mutirangura; Wichai Termrungruanglert
Journal:  Asian Pac J Cancer Prev       Date:  2020-10-01

10.  Performance of Xpert HPV on Self-collected Vaginal Samples for Cervical Cancer Screening Among Women in South Africa.

Authors:  Rakiya Saidu; Louise Kuhn; Ana Tergas; Rosalind Boa; Jennifer Moodley; Cecilia Svanholm-Barrie; David Persing; Scott Campbell; Wei-Yann Tsai; Thomas C Wright; Lynette Denny
Journal:  J Low Genit Tract Dis       Date:  2021-01-01       Impact factor: 3.842

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.